Luteolin (CED0001648)

Luteolin (C15H10O6) is a compound with an average molecular weight of 286.24 g/mol. Luteolin belongs to the flavones, a subclass of flavonoids within the organic compounds. Biologically, it functions as an antioxidant (PMC10493311, PMC12197219, PMC12210939, PMC12532804, PMC12685541, PMC2779189, PMC8398118), a polyphenol (PMC9826852), an antidepressant (PMC9958965), a ligand (PMC13095247), and an inhibitor (PMC4665427). Industrially, it is used as a softener and conditioner (PMC10493311, PMC12197219, PMC12210939, PMC12532804, PMC12685541, PMC2779189, PMC8398118). Its recorded protein targets include DNA topoisomerase 1 (TOP1), signal transducer and activator of transcription 3 (STAT3), lysophosphatidylcholine acyltransferase 1 (LPCAT1), and lysophosphatidylcholine acyltransferase 2 (LPCAT2). The compound is found in 22 recorded sources, including electrical and electronic equipment such as cell phones, capacitors, wires and cables, batteries, and printed circuit boards; food, food processing and cookware, including food packaging, molasses and treatment of molasses, and the preparation of vinegar, wine or sparkling wine, and wort; synthetic textiles, carpets and rugs; tobacco pipes and tobacco product cases; medical devices; and lubricants. Exposure routes include oral, inhalation, and touch. Luteolin is a treatment for brain ischemia (PMC6562540) and is associated with dental caries (PMC10254502). It has therapeutic effects on inflammation (PMC13095247), chronic inflammation (PMC10334012), polycystic ovary syndrome (PMC13095247), endometriosis (PMC13095247), hypertension (PMC9687696), renal fibrosis (PMC9687696), glucocorticoid-induced osteoporosis (PMC7333287), neurological dysfunction (PMC13249380), and stroke (PMC6562540). Additionally, it shows therapeutic effects on cancer (PMC12114875, PMC12197219), specifically liver cancer (PMC5666732), colon cancer (PMC12114875), breast cancer (PMC12894782), lung cancer (PMC11729017), and pulmonary fibrosis (PMC12114875).